Core Viewpoint - Novo Nordisk reported significant sales and operating profit growth for the first half of 2025, but has adjusted its full-year outlook downward due to lower growth expectations for key products like Wegovy® and Ozempic® in the US market [2][4]. Financial Performance - In the first six months of 2025, sales increased by 18% and operating profit grew by 29%, both at constant exchange rates (CER) [2]. - For the second quarter of 2025, sales growth was 18% and operating profit growth (EBIT) was 40% [3]. - The diluted earnings per share for the first half of 2025 was DKK 12.49 [3]. Updated Outlook - The full-year sales growth is now expected to be between 8-14%, down from a previous estimate of 13-21% [4]. - Operating profit growth is now projected at 10-16%, reduced from 16-24% [4]. - The lowered outlook is attributed to decreased growth expectations for Wegovy® and Ozempic® in the US, as well as lower-than-expected penetration in select markets [4][5]. Product-Specific Insights - Wegovy® sales in the US are affected by competition and slower market expansion, despite the launch of NovoCare® Pharmacy [5][7]. - Ozempic® faces similar challenges due to increased competition in the US market [9]. - The company is actively pursuing strategies to combat the impact of compounded GLP-1s and protect its market position [6]. Financial Items and Cash Flow - Novo Nordisk expects financial items (net) for 2025 to yield a gain of around DKK 3 billion, primarily from hedged currencies [12]. - Free cash flow is projected to be between DKK 35-45 billion, reflecting lower-than-expected sales growth [13].

Core Points - Novo Nordisk is focused on developing innovative medicines and ensuring accessibility and affordability for communities, particularly through the Wegovy® savings program [1] - The Wegovy® savings program has been updated to offer a 28-day supply for cash-paying patients at $499, down from the previous $650 per month [2] - NovoCare® Pharmacy provides home delivery of Wegovy® prescriptions along with support services for patients [3] Summary by Category Company Commitment - Novo Nordisk emphasizes its commitment to innovation and accessibility in healthcare, particularly for obesity management through Wegovy® [1] - The company aims to empower individuals living with obesity to achieve their health goals [1] Wegovy® Savings Program - The updated Wegovy® savings offer allows cash-paying patients or those with non-covering insurance to access a 28-day supply for $499, a reduction from the previous $650 [2] - Patients with commercial insurance that covers Wegovy® may pay as little as $0 per month, with a maximum savings of $225 for a 28-day supply [2] NovoCare® Pharmacy Services - NovoCare® Pharmacy facilitates home delivery of Wegovy® prescriptions and offers additional support such as benefit verification and refill reminders [3] - The pharmacy aims to enhance patient experience and ensure they receive authentic, FDA-approved Wegovy® [1][3]

"Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not. Today, over 55 million people in the U.S. have coverage specifically for weight management medicines, and 90% of Wegovy® patients with coverage pay $0 to $25 a month for Wegovy®," said Dave Moore, Executive Vice President, U.S. Operations and Global Business Development and President of Novo Nordisk Inc. "With NovoCare® Pharmacy, patients and prescribers alike ...